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a b s t r a c t
Metastatic prostate cancer (mPCa) relapses after a short period of androgen deprivation therapy and
becomes the castration-resistant prostate cancer (CR PCa); to which the treatment is limited. Hence, it
is imperative to identify novel therapeutic agents towards this patient population. In the present study,
antiproliferative activities of novel imidazopyridines were compared. Among three derivatives, PHE, AMD
and AMN, examined, AMD showed the highest inhibitory activity on LNCaP C-81 cell proliferation,
following dose- and time-dependent manner. Additionally, AMD exhibited significant antiproliferative
effect against a panel of PCa cells, but not normal prostate epithelial cells. Further, when compared to
AMD, its derivative DME showed higher inhibitory activities on PCa cell proliferation, clonogenic poten-
tial and in vitro tumorigenicity. The inhibitory activity was apparently in part due to the induction of
apoptosis. Mechanistic studies indicate that AMD and DME treatments inhibited both AR and PI3K/Akt
signaling. The results suggest that better understanding of inhibitory mechanisms of AMD and DME could
help design novel therapeutic agents for improving the treatment of CR PCa.
 2014 Elsevier Ireland Ltd. All rights reserved.
Introduction
Prostate cancer (PCa) is the second leading cause of cancer
deaths in United States men [1]. Androgen-deprivation therapy
(ADT) has been the mainstay of treatment towards patients with
metastatic PCa [2,3]. Although most of PCa respond well to ADT
initially, most PCa relapse and become the castration-resistant
(CR) PCa [2,3]. CR PCa is lethal with about 18-month median
survival time [4]. Currently, chemotherapy is the standard-of-care
treatment for CR PCa. Nevertheless, it only provides a minimal
improvement in survival. Hence, the prime need is to identify a
novel therapeutic agent to improve the efficacy of CR PCa
treatment.
Imidazopyridine derivatives are a class of novel compounds
which have aromatic aldehydes and a pyridine group, and possess
medicinal importance [5–7]. Recent studies show imidazopyridine
derivatives exhibit potent antitumor activity against breast and
pancreatic cancers [8,9]. Nevertheless, no report is currently avail-
able on the antiproliferative effect of imidazopyridine derivatives
on CR PCa. Therefore, the present study is undertaken to synthesize
a series of novel imidazopyridine derivatives and to investigate
their antiproliferative effect against a panel of PCa cancer cell lines
including both AR-positive and AR-negative AI PCa cells which
http://dx.doi.org/10.1016/j.canlet.2014.07.002
0304-3835/ 2014 Elsevier Ireland Ltd. All rights reserved.
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exhibit diverse phenotypes of CR PCa. Our results show that imi-
dazopyridine derivatives inhibit CR PCa cell proliferation, decrease
migration and in vitro tumorigenicity. Our data, to the best of our
knowledge, is the first report that clearly shows the potential of
this family of compounds to serve as effective molecules towards
CR PCa treatment by inhibiting AR and PI3K/Akt signaling.
Materials and methods
Materials
RPMI 1640, Keratinocyte SFM medium, gentamicin, and L-glutamine were from
Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) and charcoal/dextran-
treated FBS were purchased from Atlanta Biologicals (Lawrenceville, GA, USA). Poly-
clonal antibodies (Abs) recognizing all three isoforms of Shc protein were obtained
from Upstate (Lake Placid, NY, USA). Anti-cyclin B1, anti-cyclin D1, anti-AR,
anti-Bax, anti-BclXL, anti-PCNA, anti-p53, anti-PSA and horseradish peroxidase-
conjugated anti-mouse, anti-rabbit, anti-goat IgG Abs and Akt inhibitor (MK2206)
were all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-Akt
(Ser473) and anti-Akt Abs were from Cell Signaling Technology (Beverly, MA,
USA). Anti-b-actin Ab and DHT were obtained from Sigma (St. Louis, MO, USA).
PI3K inhibitor (LY294002) was obtained from Calbiochem (San Diego, CA, USA).
Synthesis of imidazopyridines
The synthesis of the imidazopyridine compounds were essentially followed the
protocol described in our previous publication [7]. All the reactions were performed
in flame-dried glassware under the nitrogen environment using freshly diluted sol-
vents. All the chemicals and solvents were used as received. 1H NMR (400 MHz) and
13C NMR (100 MHz) spectra were recorded with TMS as an internal standard for
reference. The C, H, and N contents were obtained through combustion analysis.
Melting points are uncorrected. The compounds were synthesized using a mixture
consisting of di-2-pyridyl ketone, substituted aromatic aldehydes and ammonium
acetate in 35 mL of glacial acetic acid [7]. Briefly, phenol, 4-actetamido-benzalde-
hyde, benzenamine and N-N-dimethyl aniline were used as substituted aldehydes
to synthesize IMP-PHE, -AMN, -AMD and -DME, respectively (Fig. 1). The reaction
was stirred at 110 C under N2 and was monitored by TLC (EtOAc:Hex = 1:1) alu-
mina plates. Upon completion, the reaction was allowed to cool to room tempera-
ture and poured into 200 mL of ice water. The yielded solid was filtered, dried, and
recrystallized with appropriate solvent to obtain an analytically pure compound [7].
Cell culture
Human prostate carcinoma cell lines LNCaP, MDA PCa2b, PC-3, DU 145 and
immortalized normal prostate epithelial cells RWPE1 and PZHPV-7 cells were all
obtained from the American Type Culture Collection (Rockville, MD, USA) and
maintained as described [10,11]. LNCaP, PC-3 and DU 145 cells were routinely
maintained in the regular culture medium, i.e., phenol red-positive RPMI 1640
medium supplemented with 5% FBS, 2 mM glutamine and 50 lg/mL gentamicin.
LNCaP C-81 cells were described previously [12,13], and exhibit the CR phenotype
including functional AR expression and prostate-specific antigen (PSA) secretion
with rapid cell growth in the steroid-deprived condition [12,13]. Further, those cells
exhibit the intracrine regulatory mechanism [14]. Similarly, MDA PCa2b-AI cells
exhibit androgen-independent (AI) proliferation and were obtained as described
[10,15,16]. MDA PCa2b-AI cells were cultured in BRFF-HPC1 medium containing
20% FBS, 2 mM glutamine and 50 lg/mL gentamicin [10,16]. RWPE1 and PZHPV-7
cells were grown in Keratinocyte-SFM supplemented with bovine pituitary extract
(25 lg/mL) and recombinant epidermal growth factor (0.15 lg/mL) containing
50 lg/mL gentamicin.
For steroid-starvation, cells were maintained in steroid-reduced (SR) media, i.e.,
phenol red-free RPMI 1640 medium containing 5% heat-inactivated, charcoal/dex-
tran-treated FBS (v/v), 2 mM glutamine, 50 lg/mL gentamicin and 1 nM 5a-dihy-
drotestosterone (DHT), which mimics the condition of androgen ablation
treatment in patients. PHE, AMN, AMD and DME were dissolved in DMSO as
1000  concentrated stock solutions, stored at 20 C, and diluted in the respective
culture media at the time of use. Control cells were treated with media containing
an equal amount of DMSO.
Cell proliferation assay
For the cell proliferation assay in regular media, LNCaP C-81 cells were plated at
a density of 2  103 cells/cm2 in 6-well plates for 3 days and then treated with
10 lM of PHE, AMN or AMD in fresh media for 3 days. To compare the effect of
AMD on different prostate cells, PCa cells and immortalized normal prostate epithe-
lia were plated in their respective regular media at the described cell density for
3 days, followed by the addition of 10 lM AMD in fresh media. The cell numbers
were counted using a Cellometer Auto T4 Image-based cell counter (Nexcelom
Bioscience), which cell number was counted by Tryphan blue exclusion assay.
The ratio of live cell number in the experimental group to that of the control group
was calculated for indicating cell proliferation.
To determine the effect of AMD and DME in SR media, C-81 cells were plated in
regular medium for 3 days and then steroid-starved for 2 days in a SR medium.
After being fed with fresh SR medium, cells were treated with different concentra-
tions of AMD or DME. Control cells were treated with solvent alone. The cell num-
bers were counted and the ratio of cell growth was calculated as described above.
Kinetics of cell growth determination
To determine the time-dependent effect of AMD and DME on the growth of
LNCaP C-81 cells, cells were seeded on six-well culture plates with triplicates and
maintained in regular culture medium for 3 days. For SR condition, cells were main-
tained for additional 48 h in SR medium. One set of attached cells from each culture
condition was harvested and counted as day 0 as described above. The remaining
attached cells were fed with fresh regular or SR medium containing solvent, AMD
or DME, and harvested on days 1, 3 and 5 for total cell number counting. The fresh
medium was added to the remaining LNCaP cells on days 1 and 3.
Immunoblot analysis
To analyze cellular proteins, cells were harvested by scraping. The cell pellet
was rinsed with ice-cold 20 mM HEPES-buffered saline (pH 7.0), lysed in ice-cold
cell lysis buffer containing protease and phosphatase inhibitors, and the total lysate
protein was prepared accordingly [12,17]. An aliquot of total cellular lysate proteins
was electrophoresed on SDS–polyacrylamide gels (7.5–12% acrylamide) for western
blot analyses [12]. The proteins of interest were visualized by an ECL detection sys-
tem. b-actin was detected as a loading control.
Cell migration
Cell migration was determined using an in vitro ‘wound-healing’ assay. Briefly,
PC-3 cells were seeded in 6-well plates and grown for 48 h to reach confluence.
Wounds were made in the confluent cell monolayer using a sterilized P200 pipette
tip. The wound was washed with RPMI medium without FBS to remove all the
detached cell debris. Remaining cells were treated with fresh media, media contain-
ing 10 lM AMD or DME. After 12 h, cells were stained with crystal violet and
images were taken. The wound gap was measured, and % wound healing was calcu-
lated. The average % of wound healing was determined by at least 3 measurements
per scratch from 2 independent experiments.
Clonogenic cell growth assay and anchorage-independent soft agar assay
The clonogenic cell growth was described previously [15,18]. Briefly, LNCaP
C-81 cells were plated in regular culture medium at densities of 20, 200, and
2000 cells per well in 6-well plates. After overnight incubation, unattached cells
Fig. 1. The structure of imidazopyridine derivatives.
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were removed and attached cells were fed with fresh regular medium with or with-
out respective compounds. 2 ml of fresh medium containing respective compound
were added into each well on days 5 and 8. On day 10, the attached cells were
stained with 0.2% crystal violet solution containing 50% methanol.
The anchorage-independent growth of cells was determined by soft agar anal-
ysis with modifications [18]. Briefly, 5  104 cells were seeded in 0.25% agarose on
the top of a base layer containing 0.3% agarose. One day after seeding, cell clumps
containing more than one cell were excluded from the study, and the cells were fed
with fresh medium containing respective treatment compounds once in every 3
days. The colony number was counted after 4 weeks of incubation at 37 C. Alterna-
tively, the colonies were stained with 0.1% crystal violet solution containing 20%
methanol and counted.
Statistical analysis
Each set of experiments was performed in duplicate or triplicate, as specified in
the figure legend or experimental design, repeated at least two or three times as
independent experiments. The mean and standard error values of experimental
results were calculated. A student-t test was used for comparison between each
group. p < 0.05 was considered statistically significant [18]. The relationship
between the relative ratios of cell proliferation and the dosage of compounds was
evaluated by their correlation coefficient (r). The correlation was considered signif-
icant when the p-value was less than 0.05.
Results
Anti-proliferative effect of imidazopyridine derivatives on LNCaP C-81
PCa cells
To determine the anti-proliferative effect of imidazopyridine
derivatives, a cell proliferation assay was initially performed in
LNCaP C-81 PCa cells because these cells exhibit many biochemical
properties of the advanced CR PCa phenotype [12–14]. After 72 h
treatment with 10 lM imidazopyridine derivatives in the regular
cell culture medium, all three compounds PHE, AMD and AMN
reduced cell proliferation by an average of 42%, 53% and 18%,
respectively (Fig. 2A). The antiproliferative activity of these com-
pounds respectively correlated with decreased protein levels of
proliferation markers cyclin B1, cyclin D1 and PCNA in those cells
(Fig. 2B). In AMD-treated LNCaP C-81 cells, AR protein level was
also decreased and tumor suppressor p53 and proapoptotic protein
Bax were elevated (Fig. 2B). Since AMD exhibited the highest inhib-
itory activity among the three compounds examined, AMD com-
pound was used for further experiments.
Dose- and time-dependent effects of AMD on LNCaP C-81 cells
We examined the dose-dependent effect of AMD on LNCaP
C-81 cells. Upon treated with 0–10 lM AMD for 72 h, cell growth
was analyzed. In regular culture media, AMD inhibited LNCaP
C-81 cell growth in a dose-dependent manner (Fig. 2C). 10 lM
AMD inhibited 54% cell growth and were used in future
experiments.
To determine the kinetic effect of AMD, at each time point, cells
in triplicates from each group were harvested and cell number
determined. The remaining cells were fed with fresh media or
media plus AMD. As shown in Fig. 2D, after 24-h treatment, cell
growth was decreased by about 19%. Upon 72-h treatment,
approximately 53% growth inhibition was observed. Five-day
treatment with 10 lM AMD inhibited the cell growth by over
60% (Fig. 2D). Thus, AMD suppressed LNCaP C-81 cell growth fol-
lowing a time course.
Antiproliferative effect of AMD on AR-positive and AR-negative PCa
cells in comparison with immortalized normal prostate epithelial cells
The growth suppressive efficacy of 10 lM AMD was evaluated
in a panel of AI cells including both AR-positive (LNCaP C-81 and
MDA PCa2b AI) and AR-negative (PC-3 and DU145) PCa cells.
Significant growth inhibition on all PCa cells tested was observed
at 10 lM AMD (Fig. 2E). Notably, 10 lM AMD had only approxi-
mately 10% effect on the proliferation of immortalized normal
prostate epithelial RWPE1 and PZHPV-7 cells (Fig. 2E). Together,
our results showed that AMD exhibits potent inhibitory activity
on AI PCa cell growth, but not normal prostate epithelia.
Comparative effects of AMD and DME in LNCaP C-81 cells
To improve the efficacy of AMD on inhibiting AI PCa cell growth,
the amino functional group of AMD was modified and a new deriv-
ative DME was obtained (Fig. 1). Preliminary experiments revealed
that 10 lM DME of 72 h-treatment decreased LNCaP C-81 cell pro-
liferation by up to 88% (p < 0.001 vs. control, data not shown);
while AMD inhibited cell growth by about 55% (data not shown
and Fig. 2A). We then examined the dose-dependent effect of
DME on LNCaP C-81 cells for 72 h. Our results showed both AMD
and DME inhibit cell growth in a dose-dependent manner
(Fig. 3A vs. 2C). In regular culture media, the efficacy of growth
inhibition by DME was about two fold that of AMD (Fig. 3) with
IC50 value of about 3.9 lM and 7.5 lM, respectively.
We analyzed the effect of AMD and DME in a SR medium con-
taining 1 nM DHT, which mimics the clinical condition under
androgen deprivation treatment. The same trend of dose-depen-
dent inhibition was observed despite the inhibitory activity was
decreased (Fig. 3B). In SR conditions, DME inhibited cell growth
with IC50 of 6.3 lM, comparing with 11.4 lM of AMD. We thus per-
formed further studies on AMD and DME at 10 lM in SR condition
for clinical relevance.
Effects of AMD and DME on cell migration and in vitro tumorigenicity
The effects of AMD and DME on PCa cell migration were
assessed by a wound healing assay with PC-3 cells as the model
system since C-81 cells exhibit slow-migration (data not shown).
As shown in Fig. 4A, both AMD and DME significantly inhibited
PC-3 cell migration. After 12 h, 50–60% of the wound area
remained open in AMD- and DME-treated cells, while the wound
in solvent-treated control group was completely closed (p < 0.01
with control).
To explore the anti-tumorigenic potential of AMD and DME, a
clonogenic assay was performed on LNCaP C-81 cells. As shown
in Fig. 4B, after 10 day-treatment, both AMD and DME inhibited
clonogenic growth. In comparison, DME inhibited clonogenic
growth at all cell densities examined, while AMD had less
inhibitory activity with colonies clearly seen in 2000 cells/well.
Nevertheless, the size of AMD-treated colony was dramatically
reduced, much smaller than controls.
An in vitro anchorage-independent soft agar assay was
performed on LNCaP C-81 cells. As shown in Fig. 4C and D, after
4-week cultured at a density of 5000 cells per 35 mm dish there
was visible colony formation in solvent-treated control groups.
AMD treatment decreased the soft agar colony number by about
50%, and DME treatment inhibited over 90% (Fig. 4D). Further, both
AMD and DME greatly reduced the size of colonies. Therefore, both
AMD and DME exhibit anti-tumorigenic effects on both AI PC-3
and LNCaP C-81 cells (Fig. 4).
Kinetics of AMD and DME effects on LNCaP C-81 cell proliferation in SR
condition
We investigated the kinetics of AMD and DME on LNCaP C-81
cell proliferation in SR conditions. As shown in Fig. 5A, after
3-day treatment in SR conditions, both AMD and DME significantly
inhibited the growth of LNCaP C-81 cells, and DME exhibited a bet-
ter efficacy than AMD. It should be noted that in SR conditions,
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while control cells continuously grew on days 3 and 5, the cell
number of AMD- and DME-treatment declined. Upon 5-day
DME-treatment, the cell number was even lower than the pre-
treatment day 0 cell number. The decrease in cell growth was
reflected by cyclin D1 protein level (Fig. 5B).
Effects of AMD and DME on AR and Shc level in SR conditions
Since the majority of CR PCa cells still express functional AR for
their growth requirement [19], we analyzed AR protein level in
AMD- and DME-treated LNCaP C-81 cells under SR condition.
Fig. 2. Effects of imidazopyridine derivatives on the growth of PCa cells in regular culture conditions. A. LNCaP C-81 cells were plated in six-well plates at 2  103 cells/cm2 in
regular medium for 3 days, then 10 lM each of imidazopyridine derivatives (PHE, AMN and AMD) in fresh medium were added for 72 h. Cells were trypsinized and counted
for live cell number. The results presented were mean ± SD; n = 2  3. ***p < 0.001. B. Total cell lysate proteins from imidazopyridine derivatives-treated C-81 cells were
analyzed for AR, p53, Bax, cyclin B1, cyclin D1, PCNA proteins. b-actin protein level was analyzed and used as a loading control. C. The dose-dependent effect of AMD on LNCaP
C-81 cell growth in regular culture medium. Cells were plated in six-well plates at 2  103 cells/cm2 in regular medium for 3 days and then treated with different
concentrations of AMD in fresh medium. After 3 days, cells were trypsinized and counted for cell growth. The results presented were mean ± SD; n = 2  3. *p < 0.05; **p < 0.01.
D. Time-dependent effect of AMD on LNCaP C-81 cell growth in regular culture condition. Cells were plated in six-well plates at 2  103 cells/cm2 in regular medium for three
days, then 10 lM AMD were added. One set of cells in triplicates was harvested after 1, 3 and 5 days, and counted for cell growth. The fresh medium was added to remaining
cells on days 1 and 3. The results presented were mean ± SE; n = 2  3. *p < 0.05; **p < 0.01. E. Effects of AMD on the growth of various PCa cells and immortalized prostate
epithelial cells. All cells were plated in six-well plates at the noted density in their respective medium for 3 days, then fresh media plus 10 lM AMD were added. After 3 days
cells were trypsinized and counted for cell number. The results presented were mean ± SE; n = 2  3. *p < 0.05; **p < 0.01; ***p < 0.001. RWPEI – 4  103 cells/cm2; PZ-HPV-7 –
6  103 cells/cm2, LNCaP C-81 – 2  103 cells/cm2; MDA PCa2b AI – 3  103 cells/cm2; PC-3 – 2  103 cells/cm2; DU145 – 2  103 cells/cm2.
62 S. Muniyan et al. / Cancer Letters 353 (2014) 59–67
Fig. 5B showed AR protein level was greatly reduced in both AMD-
and DME-treated cells at day 3 and day 5 after an initial elevation
in day 1. Concurrently, the cellular level of PSA, an androgen-
regulated protein, was closely associated with AR protein level.
Thus, AMD- and DME-treatments decrease AR signaling.
The protein level of p66Shc, a 66 kDa Src homologous-collagen
homologue (Shc), is involved in regulating the proliferation of
several carcinoma cells including PCa cells and can be up-regulated
by steroids [20–23]. Fig. 5B showed the protein level of p66Shc but
not p52Shc or p46Shc was decreased in 3-day and 5-day AMD- and
DME-treated cells. The decreased p66Shc protein level correlates
with diminished cell proliferation, AR and cyclin D1 protein levels.
Apoptotic effects of AMD and DME
We investigated whether AMD and DME suppress cell growth
in part by inducing cell apoptosis since the 5-day DME-treated cell
number was lower than the day 0 control. Bcl-XL, an anti-apoptotic
factor [24], and Bax, a proapoptotic protein [25], were analyzed in
AMD- and DME-treated cells. Treatment of LNCaP C-81 cells with
AMD and DME caused time-dependent upregulation of Bax protein
seen at day 3 and day 5 (Fig. 5C). At day 5, p53 protein, a tumor
suppressor, was also elevated in both AMD- and DME-treated cells
(Fig. 5C). In parallel, AMD and DME treatments caused a significant
decrease of Bcl-XL protein, compared to untreated control cells
(Fig. 5C). These results together indicate that induction of apopto-
sis is one mechanism by which imidazopyridine derivatives induce
growth suppression in PCa cells under steroid-reduced conditions.
Effect of AMD and DME on AR and PI3K/Akt signaling
Akt activation due to loss of PTEN activity can potentially sup-
port CR PCa formation [26–28]. In parallel, aberrant AR signaling
plays a critical role in CR PCa progression [19,29,30]. Hence, it is
proposed that the combined inhibition of AR and PI3K/Akt can
effectively improve the therapeutic efficacy in CR PCa patients.
We determined whether AMD and DME can inhibit PI3K/Akt by
examining S473 phosphorylation of Akt in LNCaP C-81 cells in
which Akt is fully activated by S473 phosphorylation [16]. We used
PI3K and Akt inhibitors for comparison. Fig. 6 showed that AMD
and DME treatments decreased the S473-phosphorylation of Akt
in addition to decreased AR and PSA proteins in LNCaP C-81 cells
(Figs. 5B and 6). As expected, both PI3K and Akt inhibitors respec-
tively reduced Akt(S473) phosphorylation (Fig. 6). Interestingly,
Akt inhibition greatly increased cellular prostatic acid phosphatase
(cPAcP) level, a tumor suppressor gene in PCa [31], but not PI3K
inhibition (Fig. 6). Unexpectedly, AR protein level was respectively
elevated following PI3K and Akt inhibitor treatments (Fig. 6). The
elevated AR expression level was corroborated by the increased
cellular PSA level.
Discussion
In androgen-dependent cells, upon androgen binding, AR is
activated and then translocated to nucleus for gene regulation,
resulting in cell growth and survival [29,30,32]. Nevertheless, CR
PCa cells, which still require functional AR, evade ligand-depen-
dent and ligand-independent mechanisms that allow cells to
survive in an androgen-depleted environment [14,29,30,32–34].
Thus, targeting multi-functional molecules simultaneously can
improve the efficacy of therapy.
In the present study, LNCaP C-81 cells were used as the primary
cell model for our studies because these cells exhibit many proper-
ties of CR PCa [12–14,33]. We first demonstrated the antiprolifera-
tive efficacy of three novel imidazopyridine derivatives on LNCaP
C-81 cells (Fig. 2). Among them, AMD effectively inhibits the cell
growth evidenced by decreased cell number and cyclin protein lev-
els (Fig. 2). Further, Bax and p53, a Bax transcription factor [34], are
upregulated in AMD-treated cells. Hence, AMD inhibits cell prolif-
eration. Importantly, while AMD has a broad spectrum of antipro-
liferative activity in both AR-positive and AR-negative AI PCa cells;
AMD spares normal prostate epithelial cells (Fig. 2E).
To improve the efficacy of growth suppression on AI PCa cells,
we modified the amino group side chain of AMD and obtained a
derivative termed DME (Fig. 1). DME exhibits superior inhibitory
activity compared to AMD on LNCaP C-81 cell growth in regular
as well as SR media (Fig. 3). While both AMD and DME effectively
inhibit LNCaP C-81 and PC-3 cell proliferation (Figs. 2, 3 and 5),
these two compounds may exhibit different mechanisms of
inhibition towards these two cell lines. For example, in the wound
healing assay, AMD was a more potent inhibitor of PC-3 cell
migration than DME. Unfortunately, LNCaP C-81 cells migrate too
slowly to conduct a wound healing assay. Conversely, in both clo-
nogenic and soft agar assays conducted on LNCaP C-81 cells, DME
was a more potent inhibitor of colony formation than AMD (Fig. 4).
One possible explanation of differential effects by DME vs. AMD is
that DME is more potent than AMD at inhibiting AR protein level
and Akt activation in C-81 cells. Additionally, PC-3 cells are
Fig. 3. Effects of AMD and DME on LNCaP C-81 cell proliferation in regular and
steroid-reduced culture conditions. A. The effects of AMD and DME on LNCaP C-81
cell growth in regular culture medium. Cells were plated in six-well plates at
2  103 cells/cm2 in regular medium for 3 days and then treated with 10 lM of
AMD and different doses of DME in fresh medium for 3 days. B. The effects of AMD
and DME on LNCaP C-81 cells in steroid-reduced condition. Cells were plated in six-
well plates at 3  103 cells/cm2 in regular medium for 3 days, followed by
maintained in steroid-reduced media containing 1 nM DHT for 2 days. AMD and
DME at different concentrations in fresh SR media containing 1 nM DHT were then
added. After 3 days of treatment, cells were trypsinized and counted for cell
numbers. The results presented were mean ± SD; n = 2  3. *p < 0.05; **p < 0.01.
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AR-negative and LNCaP C-81 cells express functional AR; as such,
DME and AMD inhibit both AR and Akt in LNCaP C-81 cells, while
only inhibit Akt in PC-3 cells. Together, DME is more potent than
AMD at inhibiting LNCaP C-81 cell proliferation and colony forma-
tion. Nevertheless, further experiments with direct comparison are
required to delineate the mechanism of growth suppression by
DME vs. AMD on these two cell lines.
Targeting AR and/or intervening with androgen biosynthesis
can effectively inhibit CR PCa and thus improve patient survival
[35–38]. Our results show for the first time that both AMD and
DME treatments can decrease AR protein and signaling with cell
growth suppression (Figs. 2, 5A and B). Although the mechanism
of AR inhibition by imidazopyridine derivatives requires further
investigation, our results show that imidazopyridine derivatives
inhibit AR-positive PCa cell growth in part by inhibiting AR signal-
ing, evidenced by decreased PSA protein (Figs. 5B and 6). It is pos-
sible that imidazopyridine derivatives decrease AR protein partly
by inhibiting Akt phosphorylation. AMD and DME inhibit Akt-
induced AR protein stability, contributing to observed lower levels
of AR protein. Furthermore, by inhibiting AR signaling, AMD and
Fig. 4. Effects of AMD and DME on PCa cell migration and tumorigenicity. A. PC-3 cells were seeded in a 6-well culture plate (1  104 cells/cm2) until 90% confluence. A
wound was created on monolayer culture using 200 ll pipette tip, and the cells were then treated with or without 10 lM AMD or DME for 12 h. At the end of the experiment,
cells were stained, photographed and the migration inhibitory-potential of AMD and DME was determined by measuring the wound closure. n = 2  4, ***p < 0.001. B. LNCaP
C-81 cells were plated in plastic wares at the densities of 20, 200 and 2000 cells/well. After 24 h the attached cells were treated with respective compounds at 10 lM
concentration of AMD and DME. The cells were fed on days 5 and 8 with fresh culture media with respective inhibitors. On day 10, the cells were stained and photographed.
The bottom picture was the enlarged version under microscope and the colony number was counted. C. LNCaP C-81 cells were plated at the densities of 5  104 cells/35 mm
dish in soft agar plates. At the end of 4 weeks, the colonies formed were stained and that from single cell was counted. Representative images of colony formation were
shown. The lower panel is microscope enlarged images. D. Number of soft agar colonies in respective groups. The results presented were mean ± SE; n = 2  4. ***p < 0.001.
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DME may prevent the interaction of AR with p85a regulatory
subunit of PI3K; which results in decreased Akt activation [39].
p66Shc, a 66 kDa oxidase, can up-regulate cell growth and is ele-
vated in steroid-regulated carcinomas [20,23,40]. In PCa, p66Shc
plays a role in mediating the cross-talk signal between steroids
and tyrosine phosphorylation [40], which is involved in regulating
cell proliferation and apoptosis [22,23,40,41]. Further, androgens
upon binding to AR can up-regulate p66Shc protein level and PCa
cell proliferation [40]. Our data show that both AMD- and DME-
treatments resulted in decreased AR and p66Shc protein levels,
correlating with diminished cell proliferation and elevated
apoptotic Bax protein (Fig. 5). Although LNCaP C-81 PCa cells are
androgen-independent cells, their growth is still increased upon
androgen treatment [13,14,19]. Thus, imidazopyridine derivatives
inhibition of AR-mediated cell growth and p66Shc protein levels
is at least in part through decreased AR protein levels. Thus,
p66Shc protein may serve as a common convergent point that
integrates cell proliferation and apoptosis signaling [23].
CR PCa cells often have elevated levels of anti-apoptotic mole-
cules for its survival [29,42]. Bcl-2 family members play critical
roles in regulating apoptosis. For example, Bcl-XL is anti-apoptosis
[43,44] and can also enhance metastasis [45]; while Bax can
Fig. 5. The kinetic effects of AMD and DME on LNCaP C-81 cells in steroid-reduced conditions. A. The cells were plated in six-well plates at 2  103 cells/cm2 in regular
medium for 3 days, then steroid starved for 48 h followed by treatment with AMD and DME at the concentration of 10 lM. After 1, 3 and 5 days, one set of cells (in duplicates)
from each group was harvested for cell number determination. The remaining cells were replenished with fresh medium and inhibitors (AMD and DME). B. Total cell lysate
proteins from AMD- and DME-treated C-81 cells were analyzed for AR, Shc, PSA and cyclin D1 protein. b-Actin protein level was used as a loading control. C. The pro-apoptotic
effect of AMD and DME on LNCaP C-81 cells in a steroid-reduced condition with time dependent manner. Total cell lysate proteins from AMD and DME treatment were
analyzed for p53, Bcl-XL and Bax proteins. b-Actin protein level was used as a loading control. The results presented were mean ± SE; n = 2  3. *p < 0.05; **p < 0.01;
***p < 0.001.
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heterodimerize with Bcl-XL and its increased level favors apoptosis
[25,46]. Further, p53 protein is a tumor suppressor, a Bax transcrip-
tional regulator [34,47] and also mediates a Bcl-2 family member-
independent apoptosis process. The elevated Bax and p53 with
decreased Bcl-XL proteins (Fig 5C) together indicate AMD and
DME can induce apoptosis. Therefore, we observed DME- and
AMD-induced growth suppression and DME-treated cells had cell
number even lower than that of day 0 control cells (Fig. 5A).
The PI3K/Akt signaling pathway plays a vital role in cell growth
and survival; its dysregulation contributes to therapeutic resis-
tance of tumor cells [26,27,29,30,48]. Our results show AMD and
DME inhibit Akt activation in addition to AR signaling (Figs. 5
and 6). Unexpectedly, treatments with both PI3K and Akt inhibi-
tors induce AR and PSA levels in PTEN-inactive LNCaP C-81 cells
(Fig. 6), which is consistent with the observation on the reciprocal
activation of AR and PI3K signaling in PTEN-deficient mouse PCa
cells [28]. Hence, the data indicate that patients treated with
PI3K pathway inhibitors can experience a rise in PSA levels if their
tumors are PTEN deficient [28]. Further, it is also hypothesized that
Akt activation may inhibit HER-2-mediated AR activation [28]. Our
results clearly show that these novel imidazopyridine derivatives
significantly inhibit both AR and PI3K/Akt signaling. Even though
targeting either AR or PI3K/AKT signaling alone by second genera-
tion inhibitors has shown promising results [28,49]; the activation
of reciprocal pathways can counteract the efficacy of inhibitors tar-
geting single signaling pathway in PCa [28,50]. Hence, combination
therapy targeting both AR and PI3K/Akt signaling molecules would
improve the therapeutic efficacy toward CR PCa.
In summary, our data show for the first time that imidazopyri-
dine derivatives can effectively inhibit CR PCa cell proliferation in
SR conditions and reduce in vitro tumorigenicity. The concurrent
inhibition of PI3K/Akt and AR signaling with the activation of apop-
totic pathway is one of the underlying mechanisms that imidazo-
pyridine derivatives suppress CR PCa cell growth. Our data thus
support the notion that the imidazopyridine derivatives represent
a promising class of compounds to combat CR PCa. Further studies
are needed to elucidate the underlying suppression mechanisms
on CR PCa cells. Modifications of other functional groups of these
compounds may further improve the efficacy of PCa suppression
for treating CR PCa.
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